Next Article in Journal
Correction: Loeber, Gerard. ISNS 9th International Symposium, The Hague, The Netherlands, September 11–14, 2016. Int. J. Neonatal Screen. 2016, 2, 5
Previous Article in Journal
Impact of Lower Screening TSH Cutoff Level on the Increasing Prevalence of Congenital Hypothyroidism
Open AccessReview

A Roadmap to Newborn Screening for Duchenne Muscular Dystrophy

Department of Pediatrics, Divisions of Neurology and Neuromuscular at Nationwide Children’s Hospital, Columbus, 43205 OH, USA
Parent Project Muscular Dystrophy, Hackensack, 07601 NJ, USA
Mark Krueger & Associates, Inc., New York, 10175 NY, USA
Center for Gene Therapy, Research Institute, Nationwide Children’s Hospital, Columbus, 43205 OH, USA
Author to whom correspondence should be addressed.
Academic Editor: Peter C.J.I. Schielen
Int. J. Neonatal Screen. 2017, 3(2), 8;
Received: 14 December 2016 / Revised: 25 February 2017 / Accepted: 28 March 2017 / Published: 7 April 2017
Duchenne muscular dystrophy (DMD) is the most common childhood form of muscular dystrophy, with an estimated frequency of 1:5000 live births. The impact of the disease presents as early as infancy with significant developmental delays, and ultimately loss of ambulation and respiratory insufficiency. Glucocorticoids are the only pharmacological agents known to alter the natural progression of the disease by prolonging ambulation, reducing scoliosis, and assisted ventilation. Introduction of therapy at an early age may halt the muscle pathology in DMD. In anticipation of the potentially disease-modifying products that are reaching regulatory review, Parent Project Muscular Dystrophy (PPMD) formally initiated a national Duchenne Newborn Screening (DNBS) effort in December 2014 to build public health infrastructure for newborn screening (NBS) for Duchenne in the United States. The effort includes a formalized national Duchenne Newborn Screening Steering Committee, six related Working Groups, a Duchenne Screening Test Development Project led by PerkinElmer, a program with the American College of Medical Genetic and Genomics’ Newborn Screening Translation Research Network (NBSTRN), and collaborations with other Duchenne partners and federal agencies involved in NBS. We herein review the organization and effort of the U.S. DNBS program to develop the evidence supporting the implementation of NBS for DMD. View Full-Text
Keywords: Duchenne; newborn screening; gene therapy; muscular dystrophy Duchenne; newborn screening; gene therapy; muscular dystrophy
Show Figures

Figure 1

MDPI and ACS Style

Al-Zaidy, S.A.; Lloyd-Puryear, M.; Kennedy, A.; Lopez, V.; Mendell, J.R. A Roadmap to Newborn Screening for Duchenne Muscular Dystrophy. Int. J. Neonatal Screen. 2017, 3, 8.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop